Can-Fite BioPharma Ltd. (CANF)

1.81
0.08 4.60
AMEX : Health Technology
Prev Close 1.73
Open 1.76
Day Low/High 1.76 / 1.95
52 Wk Low/High 1.24 / 2.75
Volume 34.13K
Avg Volume 165.20K
Exchange AMEX
Shares Outstanding 16.58M
Market Cap 33.64M
EPS -0.50
P/E Ratio 7.32
Div & Yield N.A. (N.A)

Latest News

Can-Fite To Present At BIO CEO & Investor Conference

Can-Fite To Present At BIO CEO & Investor Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, announced today...

Can-Fite Receives From Gebro Holdings $2,200,000 Payment As Part Of Distribution Agreement For Piclidenoson In 3 European Countries

Can-Fite Receives From Gebro Holdings $2,200,000 Payment As Part Of Distribution Agreement For Piclidenoson In 3 European Countries

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has...

Can-Fite 12 Months' Activities & Milestones For 2018

Can-Fite 12 Months' Activities & Milestones For 2018

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced its...

Can-Fite Signs Multi-Million Dollar Distribution Agreement For Piclidenoson In 3 European Countries With Gebro Holdings

Can-Fite Signs Multi-Million Dollar Distribution Agreement For Piclidenoson In 3 European Countries With Gebro Holdings

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has...

Data Demonstrate A Significant Anti-NASH Effect And Represent The Basis For Can-Fite's Collaborative Research Program With Dr. Safadi. (Graphic: Business Wire)

Data Demonstrate A Significant Anti-NASH Effect And Represent The Basis For Can-Fite's Collaborative Research Program With Dr. Safadi. (Graphic: Business Wire)

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the...

Can-Fite Reports On The Progress Of Its Phase II Liver Cancer With Namodenoson

Can-Fite Reports On The Progress Of Its Phase II Liver Cancer With Namodenoson

Can-Fite BioPharma Ltd. (NYSEAM:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its...

Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update

Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE MKT:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today reported financial...

Can-Fite Enrolls First Patient In Phase II NAFLD/NASH Study With Namodenoson

Can-Fite Enrolls First Patient In Phase II NAFLD/NASH Study With Namodenoson

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that...

Can-Fite's Former Subsidiary OphthaliX Successfully Completes Merger With Wize Pharma

Can-Fite's Former Subsidiary OphthaliX Successfully Completes Merger With Wize Pharma

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that...

Can-Fite Announces Enrollment Of First Patient In Its ACRobat Phase III Trial Of Piclidenoson In Rheumatoid Arthritis

Can-Fite Announces Enrollment Of First Patient In Its ACRobat Phase III Trial Of Piclidenoson In Rheumatoid Arthritis

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the...

Can-Fite Issued Patent In Korea For Piclidenoson In The Treatment Of Psoriasis

Can-Fite Issued Patent In Korea For Piclidenoson In The Treatment Of Psoriasis

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the...

Can-Fite To Present At 2017 AASLD Liver Meeting Conference In Washington, D.C.

Can-Fite To Present At 2017 AASLD Liver Meeting Conference In Washington, D.C.

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it will...

Can-Fite CEO Dr. Pnina Fishman To Present As Expert Speaker At NASH Summit Europe In Frankfurt, Germany On October 12, 2017

Can-Fite CEO Dr. Pnina Fishman To Present As Expert Speaker At NASH Summit Europe In Frankfurt, Germany On October 12, 2017

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that...

Can-Fite Files Patent Application To Treat Cytokine Release Syndrome, A Potentially Life-Threatening Complication Of CAR-T Cell Therapy

Can-Fite Files Patent Application To Treat Cytokine Release Syndrome, A Potentially Life-Threatening Complication Of CAR-T Cell Therapy

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has...

Can-Fite Receives Milestone Payment From CKD Pharmaceuticals Its Distribution Partner In Korea

Can-Fite Receives Milestone Payment From CKD Pharmaceuticals Its Distribution Partner In Korea

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has...

Can-Fite Successfully Completes Human Cardiodynamic Safety Trial For Piclidenoson

Can-Fite Successfully Completes Human Cardiodynamic Safety Trial For Piclidenoson

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced it has successfully...

Can-Fite's Phase II NAFLD/NASH Trial With Namodenoson Set To Commence Patient Enrollment Following Conclusion Of Successful Clinical Investigator Meeting

Can-Fite's Phase II NAFLD/NASH Trial With Namodenoson Set To Commence Patient Enrollment Following Conclusion Of Successful Clinical Investigator Meeting

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that it...

Can-Fite Concludes Successful Clinical Investigator Meeting For Its ACRobat Phase III Trial Of Piclidenoson In The Treatment Of Rheumatoid Arthritis

Piclidenoson is being developed as a first line therapy and replacement for the current standard of care, Methotrexate (MTX), the most widely used drug for rheumatoid arthritis

Can-Fite Establishes Clinical Advisory Board For NAFLD/NASH

- Board members are Key Opinion Leaders in the field of liver diseases

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BKD, CCE, CFBK, FIT Downgrades: FWRD, SIG, VIA Initiations: CANF Read on to get TheStreet Quant Ratings' detailed report:

Can-Fite BioPharma (CANF) Stock Jumps on Positive Pre-Clinical Data

Can-Fite BioPharma (CANF) Stock Jumps on Positive Pre-Clinical Data

Can-Fite BioPharma (CANF) stock is gaining on Monday afternoon as the company announced pre-clinical data for CF602, which demonstrated statistically significant full recovery from erectile dysfunction after a single dose.

Can-Fite BioPharma (CANF) Stock Tanks After Pricing Secondary Offering

Can-Fite BioPharma (CANF) Stock Tanks After Pricing Secondary Offering

Can-Fite BioPharma (CANF) shares are down over 10% after pricing its secondary registered direct offering of 1.1 million shares.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks trading for under $10 a share look ready to break out and trade higher from current levels.

Can-Fite BioPharma (CANF) Stock Continues to Spike Following Fast Track Designation

Can-Fite BioPharma (CANF) Stock Continues to Spike Following Fast Track Designation

Can-Fite (CANF) shares are up after the company's liver cancer treatment candidate was granted fast track designation by the FDA.

Can-Fite BioPharma (CANF) Stock Spikes on Fast Track Designation

Can-Fite BioPharma (CANF) shares are up over 40% after its liver cancer treatment candidate received FDA fast track designation.